Pyrazole bioisosteres of leflunomide as B-cell immunosuppressants for xenotransplantation and chronic rejection: Scope and limitations

Journal of Medicinal Chemistry

Volumn 41, Issue 18, 1998, Pages 3530-3538

  Papageorgiou, Christos ^a   Albert, Rainer ^a   Floersheim, Philipp ^a   Lemaire, Michel ^a   Bitch, Francis ^a   Weber, Hans Peter ^b   Andersen, Elsebeth ^a   Hungerford, Valerie ^a   Schreier, Max H ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Nova Research Services   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYL 3 (4 TRIFLUOROMETHYLPHENYL) 1H PYRAZOLE 4 CARBONITRILE; CYCLOSPORIN A; LEFLUNOMIDE; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; DOSE RESPONSE; DRUG HALF LIFE; DRUG MECHANISM; DRUG SYNTHESIS; GRAFT REJECTION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; XENOTRANSPLANTATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIGENS, T-INDEPENDENT; B-LYMPHOCYTES; CELL DIVISION; GRAFT REJECTION; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; ISOXAZOLES; JURKAT CELLS; LIPOPOLYSACCHARIDES; LYMPHOCYTE CULTURE TEST, MIXED; MICE; OXIDOREDUCTASES; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; PYRAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS;

EID: 0032572815     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm981028c     Document Type: Article

References (52)

1. Perico, N.; Remuzi, G. Prevention of transplant rejection. Current treatment guidelines and future developments. Drugs 1997, 54, 533-570.
2. Braendle, D.; Joergensen, J.; Zenke, G.; Buerki, K.; Hof, R. P. Evidence from B Cell-Deficient Mice treated with Cyclosporin A that Donor-Specific Antibodies contribute to Acute Allograft Rejection. Transplantation 1998, in press.
3. Platt, J. L. Xenotransplantation. Sci. Med. 1996, 2, 62-71. Lawson, J. H.; Platt, J. L. Molecular barriers to xenotransplantation. Transplantation 1996, 62, 303-310. Saadi, S.; Platt, J. L. Immunology of xenotransplantation. Life Sci. 1998, 62, 365-387.
4. Platt, J. L. Xenotransplantation. Sci. Med. 1996, 2, 62-71. Lawson, J. H.; Platt, J. L. Molecular barriers to xenotransplantation. Transplantation 1996, 62, 303-310. Saadi, S.; Platt, J. L. Immunology of xenotransplantation. Life Sci. 1998, 62, 365-387.
5. Platt, J. L. Xenotransplantation. Sci. Med. 1996, 2, 62-71. Lawson, J. H.; Platt, J. L. Molecular barriers to xenotransplantation. Transplantation 1996, 62, 303-310. Saadi, S.; Platt, J. L. Immunology of xenotransplantation. Life Sci. 1998, 62, 365-387.
6. Dorling, A. Strategies for preventing porcine xenograft rejection: recent progress and future developments. Exp. Opin. Ther. Patents 1997, 7, 1307-1319.
7. Dalamsso, A. P.; Bach, F. H. Expression of human regulators of complement on pig endothelial cells. Xenotransplantation 1996, 4, 55-57. Cozzi, E.; White, D. J. G. The generation of transgenic pigs as potential organ donors for humans. Nature Med. 1995, 1, 964-966.
8. Dalamsso, A. P.; Bach, F. H. Expression of human regulators of complement on pig endothelial cells. Xenotransplantation 1996, 4, 55-57. Cozzi, E.; White, D. J. G. The generation of transgenic pigs as potential organ donors for humans. Nature Med. 1995, 1, 964-966.
9. Lin, Y.; Goebels, J.; Xia, G.; Ji, P.; Vandeputte, M.; Waer, M. Induction of specific transplantation tolerance across xenogeneic barriers in the T-independent immune compartment. Nature Med. 1998, 4, 173-180.
10. Lawson, J. H.; Daniels, L. J.; Hoopes, C. W.; Lin, S. S.; Weidner, B. C.; Mccurry, K. R.; Davis, R. D.; Bollinger, R. R.; Harland, R. C.; Logan, J.; Diamond, L. E.; Martin, M.; Byrne, G.; Platt, J. L. The role of transgenic expression of human complement regulatory proteins in discordant xenotransplantation. Surg. Forum 1997, 48, 487-489 Leventhal, J. R.; Sakiyalak, P.; Witson, J.; Simone, P.; Matas, A. J.; Bolman, R. M.; Dalmasso, A. P. The synergistic effect of combined antibody and complement depletion on discordant cardiac xenograft survival in non-human primates. Transplantation 1994, 57, 974-977. Leventhal, J. R.; Matas, A. J.; Sun, L. H.; Reif, S.; Bolman, R. M.; Dalmasso, A. P.; Platt, J. L. The immunopathology of cardiac xenograft rejection in the guinea pig-to-rat model. Transplantation 1993, 56, 1-8. Blakely, M. L.; van der Werf, W. J.; Berndt, M. C.; Dalmasso, A. P.; Bach, F. H.; Hancock, W. W. Activation of intragraft endothelial and mononuclear cells during discordant xenograft rejection. Transplantation 1994, 58, 1059-1066. Soheyla, S.; Platt, J. L. Immunology of Xenotransplantation. Life Sci. 1997, 62, 365-387.
11. Lawson, J. H.; Daniels, L. J.; Hoopes, C. W.; Lin, S. S.; Weidner, B. C.; Mccurry, K. R.; Davis, R. D.; Bollinger, R. R.; Harland, R. C.; Logan, J.; Diamond, L. E.; Martin, M.; Byrne, G.; Platt, J. L. The role of transgenic expression of human complement regulatory proteins in discordant xenotransplantation. Surg. Forum 1997, 48, 487-489 Leventhal, J. R.; Sakiyalak, P.; Witson, J.; Simone, P.; Matas, A. J.; Bolman, R. M.; Dalmasso, A. P. The synergistic effect of combined antibody and complement depletion on discordant cardiac xenograft survival in non-human primates. Transplantation 1994, 57, 974-977. Leventhal, J. R.; Matas, A. J.; Sun, L. H.; Reif, S.; Bolman, R. M.; Dalmasso, A. P.; Platt, J. L. The immunopathology of cardiac xenograft rejection in the guinea pig-to-rat model. Transplantation 1993, 56, 1-8. Blakely, M. L.; van der Werf, W. J.; Berndt, M. C.; Dalmasso, A. P.; Bach, F. H.; Hancock, W. W. Activation of intragraft endothelial and mononuclear cells during discordant xenograft rejection. Transplantation 1994, 58, 1059-1066. Soheyla, S.; Platt, J. L. Immunology of Xenotransplantation. Life Sci. 1997, 62, 365-387.
12. Lawson, J. H.; Daniels, L. J.; Hoopes, C. W.; Lin, S. S.; Weidner, B. C.; Mccurry, K. R.; Davis, R. D.; Bollinger, R. R.; Harland, R. C.; Logan, J.; Diamond, L. E.; Martin, M.; Byrne, G.; Platt, J. L. The role of transgenic expression of human complement regulatory proteins in discordant xenotransplantation. Surg. Forum 1997, 48, 487-489 Leventhal, J. R.; Sakiyalak, P.; Witson, J.; Simone, P.; Matas, A. J.; Bolman, R. M.; Dalmasso, A. P. The synergistic effect of combined antibody and complement depletion on discordant cardiac xenograft survival in non-human primates. Transplantation 1994, 57, 974-977. Leventhal, J. R.; Matas, A. J.; Sun, L. H.; Reif, S.; Bolman, R. M.; Dalmasso, A. P.; Platt, J. L. The immunopathology of cardiac xenograft rejection in the guinea pig-to-rat model. Transplantation 1993, 56, 1-8. Blakely, M. L.; van der Werf, W. J.; Berndt, M. C.; Dalmasso, A. P.; Bach, F. H.; Hancock, W. W. Activation of intragraft endothelial and mononuclear cells during discordant xenograft rejection. Transplantation 1994, 58, 1059-1066. Soheyla, S.; Platt, J. L. Immunology of Xenotransplantation. Life Sci. 1997, 62, 365-387.
13. Lawson, J. H.; Daniels, L. J.; Hoopes, C. W.; Lin, S. S.; Weidner, B. C.; Mccurry, K. R.; Davis, R. D.; Bollinger, R. R.; Harland, R. C.; Logan, J.; Diamond, L. E.; Martin, M.; Byrne, G.; Platt, J. L. The role of transgenic expression of human complement regulatory proteins in discordant xenotransplantation. Surg. Forum 1997, 48, 487-489 Leventhal, J. R.; Sakiyalak, P.; Witson, J.; Simone, P.; Matas, A. J.; Bolman, R. M.; Dalmasso, A. P. The synergistic effect of combined antibody and complement depletion on discordant cardiac xenograft survival in non-human primates. Transplantation 1994, 57, 974-977. Leventhal, J. R.; Matas, A. J.; Sun, L. H.; Reif, S.; Bolman, R. M.; Dalmasso, A. P.; Platt, J. L. The immunopathology of cardiac xenograft rejection in the guinea pig-to-rat model. Transplantation 1993, 56, 1-8. Blakely, M. L.; van der Werf, W. J.; Berndt, M. C.; Dalmasso, A. P.; Bach, F. H.; Hancock, W. W. Activation of intragraft endothelial and mononuclear cells during discordant xenograft rejection. Transplantation 1994, 58, 1059-1066. Soheyla, S.; Platt, J. L. Immunology of Xenotransplantation. Life Sci. 1997, 62, 365-387.
14. Lawson, J. H.; Daniels, L. J.; Hoopes, C. W.; Lin, S. S.; Weidner, B. C.; Mccurry, K. R.; Davis, R. D.; Bollinger, R. R.; Harland, R. C.; Logan, J.; Diamond, L. E.; Martin, M.; Byrne, G.; Platt, J. L. The role of transgenic expression of human complement regulatory proteins in discordant xenotransplantation. Surg. Forum 1997, 48, 487-489 Leventhal, J. R.; Sakiyalak, P.; Witson, J.; Simone, P.; Matas, A. J.; Bolman, R. M.; Dalmasso, A. P. The synergistic effect of combined antibody and complement depletion on discordant cardiac xenograft survival in non-human primates. Transplantation 1994, 57, 974-977. Leventhal, J. R.; Matas, A. J.; Sun, L. H.; Reif, S.; Bolman, R. M.; Dalmasso, A. P.; Platt, J. L. The immunopathology of cardiac xenograft rejection in the guinea pig-to-rat model. Transplantation 1993, 56, 1-8. Blakely, M. L.; van der Werf, W. J.; Berndt, M. C.; Dalmasso, A. P.; Bach, F. H.; Hancock, W. W. Activation of intragraft endothelial and mononuclear cells during discordant xenograft rejection. Transplantation 1994, 58, 1059-1066. Soheyla, S.; Platt, J. L. Immunology of Xenotransplantation. Life Sci. 1997, 62, 365-387.
15. Häry, P. Molecular Pathology of Acute and Chronic Rejection. Transplant. Proc. 1994, 26, 3280-3284. Azuma, H.; Tilney, N. L. Chronic graft rejection. Curr. Opin. Immunol. 1994, 6, 770-776.
16. Häry, P. Molecular Pathology of Acute and Chronic Rejection. Transplant. Proc. 1994, 26, 3280-3284. Azuma, H.; Tilney, N. L. Chronic graft rejection. Curr. Opin. Immunol. 1994, 6, 770-776.
17. Hess, M. L.; Hastillo, A.; Mohanakumar, D. V. M.; Cowley, M. J.; Vetrovac, G.; Szentpetery, S.; Wolfgang, T. C.; Lower, R. R. Accelerated atherosclerosis in cardiac transplantation: role of cytotoxic B-cell antibodies and hyperlidemia. Circulation 1983, 68 (Suppl. II), II-94, II-101. Diethelm, A. G.; Deierhoi, M. H.; Hudson, S. L.; Laskow, D. A.; Julian, B. A.; Gaston, R. S.; Bynon, J. S.; Cutris, J. J. Progress in renal transplantation. A single center study of 3359 patients over 25 years. Ann. Surg. 1995, 221, 446-457. Lobo, P. I.; Spencer, C. E.; Stevenson, W. C.; Pruett, T. L. Evidence demonstrating poor kidney graft survival when acute rejections are associated with IgG donor-specific lymphocytotoxin. Transplantation 1995, 59, 357-360. Suciu-Foca, N.; Reed, E.; Marboe, C.; Harris, P.; Xi, Y. P.; Yu-Kai, S.; Ho, E.; Rose, E.; Reemtsma, K.; King, D. W. The role of Anti-HLA Antibodies in Heart Transplantation. Transplantation 1991, 57, 716-724. Winter, J. B.; Clelland, C.; Gouw, A. S.; Prop, J. Distinct phenotypes of infiltrating cells during acute and chronic lung rejection in human heart-lung transplants. Transplantation 1995, 59, 63-69.
18. Hess, M. L.; Hastillo, A.; Mohanakumar, D. V. M.; Cowley, M. J.; Vetrovac, G.; Szentpetery, S.; Wolfgang, T. C.; Lower, R. R. Accelerated atherosclerosis in cardiac transplantation: role of cytotoxic B-cell antibodies and hyperlidemia. Circulation 1983, 68 (Suppl. II), II-94, II-101. Diethelm, A. G.; Deierhoi, M. H.; Hudson, S. L.; Laskow, D. A.; Julian, B. A.; Gaston, R. S.; Bynon, J. S.; Cutris, J. J. Progress in renal transplantation. A single center study of 3359 patients over 25 years. Ann. Surg. 1995, 221, 446-457. Lobo, P. I.; Spencer, C. E.; Stevenson, W. C.; Pruett, T. L. Evidence demonstrating poor kidney graft survival when acute rejections are associated with IgG donor-specific lymphocytotoxin. Transplantation 1995, 59, 357-360. Suciu-Foca, N.; Reed, E.; Marboe, C.; Harris, P.; Xi, Y. P.; Yu-Kai, S.; Ho, E.; Rose, E.; Reemtsma, K.; King, D. W. The role of Anti-HLA Antibodies in Heart Transplantation. Transplantation 1991, 57, 716-724. Winter, J. B.; Clelland, C.; Gouw, A. S.; Prop, J. Distinct phenotypes of infiltrating cells during acute and chronic lung rejection in human heart-lung transplants. Transplantation 1995, 59, 63-69.
19. Hess, M. L.; Hastillo, A.; Mohanakumar, D. V. M.; Cowley, M. J.; Vetrovac, G.; Szentpetery, S.; Wolfgang, T. C.; Lower, R. R. Accelerated atherosclerosis in cardiac transplantation: role of cytotoxic B-cell antibodies and hyperlidemia. Circulation 1983, 68 (Suppl. II), II-94, II-101. Diethelm, A. G.; Deierhoi, M. H.; Hudson, S. L.; Laskow, D. A.; Julian, B. A.; Gaston, R. S.; Bynon, J. S.; Cutris, J. J. Progress in renal transplantation. A single center study of 3359 patients over 25 years. Ann. Surg. 1995, 221, 446-457. Lobo, P. I.; Spencer, C. E.; Stevenson, W. C.; Pruett, T. L. Evidence demonstrating poor kidney graft survival when acute rejections are associated with IgG donor-specific lymphocytotoxin. Transplantation 1995, 59, 357-360. Suciu-Foca, N.; Reed, E.; Marboe, C.; Harris, P.; Xi, Y. P.; Yu-Kai, S.; Ho, E.; Rose, E.; Reemtsma, K.; King, D. W. The role of Anti-HLA Antibodies in Heart Transplantation. Transplantation 1991, 57, 716-724. Winter, J. B.; Clelland, C.; Gouw, A. S.; Prop, J. Distinct phenotypes of infiltrating cells during acute and chronic lung rejection in human heart-lung transplants. Transplantation 1995, 59, 63-69.
20. Hess, M. L.; Hastillo, A.; Mohanakumar, D. V. M.; Cowley, M. J.; Vetrovac, G.; Szentpetery, S.; Wolfgang, T. C.; Lower, R. R. Accelerated atherosclerosis in cardiac transplantation: role of cytotoxic B-cell antibodies and hyperlidemia. Circulation 1983, 68 (Suppl. II), II-94, II-101. Diethelm, A. G.; Deierhoi, M. H.; Hudson, S. L.; Laskow, D. A.; Julian, B. A.; Gaston, R. S.; Bynon, J. S.; Cutris, J. J. Progress in renal transplantation. A single center study of 3359 patients over 25 years. Ann. Surg. 1995, 221, 446-457. Lobo, P. I.; Spencer, C. E.; Stevenson, W. C.; Pruett, T. L. Evidence demonstrating poor kidney graft survival when acute rejections are associated with IgG donor-specific lymphocytotoxin. Transplantation 1995, 59, 357-360. Suciu-Foca, N.; Reed, E.; Marboe, C.; Harris, P.; Xi, Y. P.; Yu-Kai, S.; Ho, E.; Rose, E.; Reemtsma, K.; King, D. W. The role of Anti-HLA Antibodies in Heart Transplantation. Transplantation 1991, 57, 716-724. Winter, J. B.; Clelland, C.; Gouw, A. S.; Prop, J. Distinct phenotypes of infiltrating cells during acute and chronic lung rejection in human heart-lung transplants. Transplantation 1995, 59, 63-69.
21. Hess, M. L.; Hastillo, A.; Mohanakumar, D. V. M.; Cowley, M. J.; Vetrovac, G.; Szentpetery, S.; Wolfgang, T. C.; Lower, R. R. Accelerated atherosclerosis in cardiac transplantation: role of cytotoxic B-cell antibodies and hyperlidemia. Circulation 1983, 68 (Suppl. II), II-94, II-101. Diethelm, A. G.; Deierhoi, M. H.; Hudson, S. L.; Laskow, D. A.; Julian, B. A.; Gaston, R. S.; Bynon, J. S.; Cutris, J. J. Progress in renal transplantation. A single center study of 3359 patients over 25 years. Ann. Surg. 1995, 221, 446-457. Lobo, P. I.; Spencer, C. E.; Stevenson, W. C.; Pruett, T. L. Evidence demonstrating poor kidney graft survival when acute rejections are associated with IgG donor-specific lymphocytotoxin. Transplantation 1995, 59, 357-360. Suciu-Foca, N.; Reed, E.; Marboe, C.; Harris, P.; Xi, Y. P.; Yu-Kai, S.; Ho, E.; Rose, E.; Reemtsma, K.; King, D. W. The role of Anti-HLA Antibodies in Heart Transplantation. Transplantation 1991, 57, 716-724. Winter, J. B.; Clelland, C.; Gouw, A. S.; Prop, J. Distinct phenotypes of infiltrating cells during acute and chronic lung rejection in human heart-lung transplants. Transplantation 1995, 59, 63-69.
22. Shi, C.; Lee, W.-S.; He, Q.; Zhang, D.; Fletcher, D. L.; Newell, J. B.; Haber, E. Immunological basis of transplant-associated arteriosclerosis. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 4051-4056.
23. Silva, H. T.; Morris, R. E. Leflunomide and malononitriloamides. Exp. Opin. Invest. Drugs 1997, 6, 51-64.
24. Lucien, J.; Marath, A.; Rayat, G.; Koshal, A.; Yatscoff, R. Efficacy of Leflunomide to Reduce Xenoantibody Titers In Vivo: An Evaluation of the Prolongation of Discordant Xenograft Survival. Transplant. Proc. 1996, 28, 704-707. Lin, Y.; Sobis, H.; Vandeputte, M.; Waer, M. Long-Term Xenograft Survival and Suppression of Xenoantibody Formation in the Hamster-to-Rat Heart Transplant Model Using a Combination Therapy of Leflunomide and Cyclosporin. Transplant. Proc. 1994, 26, 3202. Xiao, F.; Chong, A.; Foster, P.; Sankary, H.; McChesney, L.; Koukoulis, G.; Yang, J.; Frieders, D.; Williams, J. W. Leflunomide Controls Rejection in Hamster to Rat Cardiac Xenografts. Transplantation 1994, 58, 828-834. Lin, Y.; Sobis, H.; Vandeputte, M.; Waer, M. Mechanism of Leflunomide-Induced Prevention of Xenoantibody Formation and Xenograft Rejection in the Hamster to Rat Heart Transplantation Model. Transplant. Proc. 1995, 27, 305-306.
25. Lucien, J.; Marath, A.; Rayat, G.; Koshal, A.; Yatscoff, R. Efficacy of Leflunomide to Reduce Xenoantibody Titers In Vivo: An Evaluation of the Prolongation of Discordant Xenograft Survival. Transplant. Proc. 1996, 28, 704-707. Lin, Y.; Sobis, H.; Vandeputte, M.; Waer, M. Long-Term Xenograft Survival and Suppression of Xenoantibody Formation in the Hamster-to-Rat Heart Transplant Model Using a Combination Therapy of Leflunomide and Cyclosporin. Transplant. Proc. 1994, 26, 3202. Xiao, F.; Chong, A.; Foster, P.; Sankary, H.; McChesney, L.; Koukoulis, G.; Yang, J.; Frieders, D.; Williams, J. W. Leflunomide Controls Rejection in Hamster to Rat Cardiac Xenografts. Transplantation 1994, 58, 828-834. Lin, Y.; Sobis, H.; Vandeputte, M.; Waer, M. Mechanism of Leflunomide-Induced Prevention of Xenoantibody Formation and Xenograft Rejection in the Hamster to Rat Heart Transplantation Model. Transplant. Proc. 1995, 27, 305-306.
26. Lucien, J.; Marath, A.; Rayat, G.; Koshal, A.; Yatscoff, R. Efficacy of Leflunomide to Reduce Xenoantibody Titers In Vivo: An Evaluation of the Prolongation of Discordant Xenograft Survival. Transplant. Proc. 1996, 28, 704-707. Lin, Y.; Sobis, H.; Vandeputte, M.; Waer, M. Long-Term Xenograft Survival and Suppression of Xenoantibody Formation in the Hamster-to-Rat Heart Transplant Model Using a Combination Therapy of Leflunomide and Cyclosporin. Transplant. Proc. 1994, 26, 3202. Xiao, F.; Chong, A.; Foster, P.; Sankary, H.; McChesney, L.; Koukoulis, G.; Yang, J.; Frieders, D.; Williams, J. W. Leflunomide Controls Rejection in Hamster to Rat Cardiac Xenografts. Transplantation 1994, 58, 828-834. Lin, Y.; Sobis, H.; Vandeputte, M.; Waer, M. Mechanism of Leflunomide-Induced Prevention of Xenoantibody Formation and Xenograft Rejection in the Hamster to Rat Heart Transplantation Model. Transplant. Proc. 1995, 27, 305-306.
27. Lucien, J.; Marath, A.; Rayat, G.; Koshal, A.; Yatscoff, R. Efficacy of Leflunomide to Reduce Xenoantibody Titers In Vivo: An Evaluation of the Prolongation of Discordant Xenograft Survival. Transplant. Proc. 1996, 28, 704-707. Lin, Y.; Sobis, H.; Vandeputte, M.; Waer, M. Long-Term Xenograft Survival and Suppression of Xenoantibody Formation in the Hamster-to-Rat Heart Transplant Model Using a Combination Therapy of Leflunomide and Cyclosporin. Transplant. Proc. 1994, 26, 3202. Xiao, F.; Chong, A.; Foster, P.; Sankary, H.; McChesney, L.; Koukoulis, G.; Yang, J.; Frieders, D.; Williams, J. W. Leflunomide Controls Rejection in Hamster to Rat Cardiac Xenografts. Transplantation 1994, 58, 828-834. Lin, Y.; Sobis, H.; Vandeputte, M.; Waer, M. Mechanism of Leflunomide-Induced Prevention of Xenoantibody Formation and Xenograft Rejection in the Hamster to Rat Heart Transplantation Model. Transplant. Proc. 1995, 27, 305-306.
28. MacDonald, A. S.; Sabr, K.; MacAuley, M. A.; McAlister, V. C.; Bitter-Suermann, H.; Lee, T. Effects of Leflunomide and Cyclosporin on Aortic Allograft Chronic Rejection in the Rat. Transplant. Proc. 1994, 26, 3244-3245.
29. Morris, R. E.; Huang, X.; Gregory, C. R.; Billingham, M. E.; Rowan, R.; Shorthouse, R.; Berry, G. J. Studies in Experimental Models of Chronic Rejection: Use of Rapamycin and Isoxazole Derivatives for the Suppression of Graft Vascular Disease and Obliterative Bronchiolitis. Transplant. Proc. 1995, 27, 2068-2069.
30. Swan, S. K.; Grary, G. S.; Guijarro, C.; O'Donnell, M. P.; Keane, W. F.; Kasiske, B. L. Immunosuppressive Effects of leflunomide in Experimental Chronic Vascular Rejection. Transplantation 1995, 60, 887-890.
31. Xiao, F.; Chong, A.; Shen, J.; Yang, J.; Short, J.; Foster, P.; Sankary, H.; Jensik, S.; Mital, D.; McChesney, L.; Koukoulis, G.; Williams, J. W. Pharmacologically Induced Regression of Chronic Transplant Rejection. Transplantation 1995, 60, 1065-1072.
32. Dias, V. C.; Lucien, J.; LeGatt, D. F.; Yatscoff, R. W. Measurement of the Active Leflunomide Metabolite by Reverse-Phase High-Performance Liquid Chromatography. Ther. Drug Monitor. 1995, 17, 84-88.
33. Kuo, E. A.; Hambleton, P. T.; Kay, D. P.; Evans, P. L.; Matharu, S. S.; Little, E.; McDowall, N.; Jones, B. C.; Hedgecock, C. J. R.; Yea, C. M.; Chan, E. A. W.; Hairsine, P. W.; Ager, I. A.; Tully, R. W.; Williamson, R. A.; Westwood, R. J. Med. Chem. 1996, 39, 4608-4612.
34. Shuurman, H.-J.; Tanner, M. Unpublished results (NOVARTIS Pharma AG).
35. Papageorgiou, C.; Zurini, M.; Weber, H.-P.; Borer, X. Leflunomide's Bioactive Metabolite Has the Minimal Structural Requirements for the Efficient Inhibition of Human Dihydroorotate Dehydrogenase. Bioorg. Chem. 1997, 25, 233-238.
36. Papageorgiou, C.; Kayan, A.; Oberer, L.; Borer, X.; Rihs, G. Hydroxy- and Alkoxy-Cyanopropenamides: Synthesis, Structure and Solvent Dependent (E)/(Z) Isomerisation. Helv. Chim. Acta 1998, 81, 1319-1328.
37. Bertolini, G.; Aquino, M.; Biffi, M.; d'Atri, G.; Di Pierro, F.; Ferrario, F.; Mascagni, P.; Somenzi, F.; Zaliani, A.; Leoni, F. A New Rational Hypothesis for the Pharmacophore of the active Metabolite of Leflunomide, a Potent Immunosuppressive Drug. J. Med. Chem. 1997, 40, 2011-2016.
38. Ibrahim, N. S. Reaction of isothiocyanates with active methylene reagent: a new approach for the synthesis of pyrazole, pyrimidine and pyrazolo[1,5-a]pyrimidine derivatives. Chem. Ind. 1989, 654-655.
39. Mohareb, R. M.; Shams, H. Z.; Aziz, S. I. Reactions with 4-Phenyl-3-thiosemicarbazide: A New Approach for the Synthesis of Pyrazole, Thiazole, Pyridine and Pyrazolo[3,4-b]-pyridine derivatives. Sulfur Lett. 1991, 13, 101-113.
40. Vishwakarma, J. N.; Chowdhury, B. K.; Roy, H.; Jumjappa, H. Reactions of polarized ketene S,N-acetals with hydrazine: a facile general route to 3(5)-substituted amino-4,5(3)-substituted pyrazoles. Part XLV. Indian J. Chem., Sect. B 1985, 24B, 472-476.
41. Hackler, R. E.; Wickiser, D. I. 3-Substituted 3-aminonitriles. Patent GB 2141712 A, Jan 3, 1985.
42. Lang, S. A.; Cohen, E. β-Aminocinnamonitriles as potent antiinflammatory agents. J. Med. Chem. 1975, 18, 441-443.
43. Suesse, M.; Johne, S. Synthese von Chinazolin-4-thion- und 1H-Indazol-Derivaten. (Synthesis of Quinazoline-4-thiones and 1H-Indazole Derivatives.) J. Prakt. Chem. 1986, 328, 635-639.
44. Goerdeler, J.; Laqua, A.; Linder, C. Imidoylketene imines. II. Preparartion of vinylogous thioureas and isothioureas. Chem. Ber. 1974, 107, 3518-3532.
45. Radl, S. Preparation of some pyrazole derivatives by extrusion of elemental sulfur from 1,3,4-thiadiazines. Collect. Czech. Chem. Commun. 1992, 5, 656-659.
46. Taylor, R.; Kennard, O. Crystallographic Evidence for Existence of C-H⋯O, C-H⋯N, and C-H⋯Cl Hydrogen Bonds. J. Am. Chem. Soc. 1982, 104, 5063-5070.
47. The molecular modeling program packet Sybyl6.4_r4, from Evans & Sutherland, Tripos Assoc. Inc., St. Louis, MO, was used.
48. Kallen, J.; Mikol, V.; Quesniaux, V.; Walkinshaw, M. D.; Schneider-Scherzer, E.; Schorgendorfer, K.; Weber, G.; Fliri, H. G. Cyclosporins: recent developments in biosynthesis, pharmacology and biology, and clinical applications. In Biotechnology, 2nd ed.; Kleinkauf, H., Von Doehren, H., Eds.; VCH: Weinheim, Germany, 1997; pp 535-591.
49. Meo, T. The MLR test in the mouse. In Immunological Methods; Lefkovits, I., Pernis, B., Eds.; Academic Press: New York, 1979; pp 227-239.
50. Davies, J. P.; Cain, G. A.; Pitts, W. J.; Magolda, R. L.; Copeland, R. A. Biochemistry 1996, 35, 1270-1273.
51. Fersht, A. R. The hydrogen bond in molecular recognition. Trends Biol. Sci. 1987, 13, 301-304.
52. Schreier, M. H.; Tees, R. Long-term culture and cloning of specific helper T cells. In Immunological Methods; Lefkovits, I., Pernis, B., Eds.; Academic Press: New York, 1981; pp 263-275.